Navigation Links
Breast cancer risk varies significantly among BRCA1 and BRCA2 carriers
Date:1/8/2008

There is a broad variation in the risk of developing breast cancer among people who carry the BRCA1 and BRCA2 gene mutation, according to a study in the January 9/16 issue of JAMA.

BRCA1 and BRCA2 are gene mutations that predispose carriers to breast cancer. The magnitude of the risk of breast cancer in BRCA1 and BRCA2 carriers is critical for guiding decisions concerning cancer prevention options. The risk of breast cancer in BRCA1 and BRCA2 mutation carriers has been examined in many studies, but relatively little attention has been paid to the degree to which the risk may vary among carriers, according to background information in the article.

Colin B. Begg, Ph.D., of Memorial Sloan-Kettering Cancer Center, New York, and colleagues conducted an investigation to determine the extent to which risks of BRCA1 and BRCA2 carriers vary with respect to observable and unobservable characteristics. Participants in the Womens Environmental Cancer and Radiation Epidemiology (WECARE) Study, who were previously diagnosed with unilateral breast cancer (affecting only one side) or contralateral breast cancer (affecting the opposite side of an initial breast cancer), were genotyped for mutations in BRCA1 and BRCA2. All participants had their initial breast cancer diagnosed during the period from January 1985 through December 2000, before the age of 55.

Among the 1,394 participants with unilateral breast cancer, 73 (5.2 percent) were identified as carriers of deleterious mutations (42 with BRCA1 and 31 with BRCA2), the authors report. Among the 704 participants with contralateral breast cancer, 108 (15.3 percent) were identified as carriers of deleterious mutations (67 with BRCA1 and 41 with BRCA2).

Among relatives of BRCA1 and BRCA2 carriers, risk was significantly associated with a younger age at diagnosis in the proband (the family member through whom a familys medical history comes to light). There was a trend toward higher risk for relatives of participants with contralateral breast cancer vs. unilateral breast cancer participants. In addition, there were significant differences in risk between carrier families after adjusting for these observed characteristics, the authors write.

Population-based screening for BRCA1 and BRCA2 mutations is not recommended at this time. But the authors point out that in the future, as technology advances and genotyping costs are reduced, widespread genetic screening for important risk factors for breast cancer and other diseases may become routine and is likely to serve as the foundation for tailored risk reduction interventions.

For this reason, accurate estimation of the risks conferred in the population and identification of important sources of variation in these risks constitute important scientific goals with significant implications for the clinical management of female carriers of BRCA1 and BRCA2 mutations, the authors conclude.


'/>"/>

Contact: Jeanne D'Agostino
646-227-3573
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. BRCA Mutations Dont Raise Breast Cancer Risk Equally
2. American women are more likely to choose overly aggressive treatments for breast cancer
3. Breast-Feeding Seems to Protect Against Some Allergies
4. Breast Is Best for Reducing Stress
5. Localized Breast Cancer Cells Have Potential to Spread
6. Susan G. Komen for the Cure, Ryan Community Health Centers, Breast Cancer Survivors Call on New York State to Expand Breast Cancer Screening, Treatment Programs
7. ASPS Studies Re-Evaluate Psychological Benefits and Health Concerns of Silicone Breast Implants
8. Breast Cancer Gene Might Extend Ovarian Cancer Survival
9. Bevacizumab found to improve survival for patients with advanced breast cancer
10. Class of Chemotherapy Drugs Helps Certain Breast Cancer Patients
11. Chemotherapy and tamoxifen reduce risk of second breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... Va. (PRWEB) , ... September 21, 2017 , ... ... with a different approach to addiction recovery at a time when Virginia faces ... deaths resulting from drug overdose, a staggering increase of 38 percent from 2015, ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... the acquisition of Isle at Kingwood Assisted Living and Memory Care located at ... retirement community with 55 assisted living apartments, 43 memory care apartments and 23 ...
(Date:9/21/2017)... ... September 21, 2017 , ... In ... and Clark College Emeritus Professor of Education Gregory A. Smith examines student privacy ... Asleep at the Switch: Schoolhouse Commercialism, Privacy, and the Failure of Policymaking . ...
(Date:9/20/2017)... CHARLOTTE, NC (PRWEB) , ... September 20, 2017 ... ... for Transformation and Centers of Excellence (CoE) with the latest Artificial Intelligence (AI) ... newly designed presence offers quick and easy access to essential information that offers ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... one of the Best Places to Work in the Research Triangle for 2017. ... Once nominated, a company had to meet a threshold in employee participation--a percentage ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... Ind. , Sept. 7, 2017  Zimmer Biomet ... in musculoskeletal healthcare, today announced that it will be ... Global Healthcare Conference at the Grand Hyatt hotel in ... 11, 2017 at 11:40 a.m. Eastern Time. ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
(Date:9/6/2017)... Sept. 6, 2017 NeuroRx, a clinical stage biopharma ... and Behavior (ASIB), has been granted Fast Track status by ... of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). ... trial of this sequential therapy targeting patients who are admitted ... ...
(Date:9/5/2017)... LONDON , Sept. 5, 2017  Just 18 ... Valid Insight is pleased to announce the appointment of ... Tammy Wynne , Dominic Jones-Phillips and ... from industry. ... a team of market access writers. She has over ...
Breaking Medicine Technology: